SCHEMBL6470519

SCHEMBL6470519

CCC1(C(N)=O)CCCCC1(OC(F)(F)F)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.35
PRCP P42785 2/20 0.35
SIGMAR1 Q99720 2/20 0.35
OPRM1 P35372 4/20 0.35
OPRD1 P41143 2/20 0.35
OPRK1 P41145 2/20 0.35
AKR1C1 Q04828 1/20 0.35
ALDH1A1 P00352 3/20 0.34
POLB P06746 1/20 0.34
APOBEC3A P31941 3/20 0.34
APOBEC3G Q9HC16 3/20 0.34
HTT P42858 2/20 0.34
NR1H2 P55055 2/20 0.34
NR1H3 Q13133 2/20 0.34
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CHRM2 P08172 2/20 0.33
CHRM1 P11229 2/20 0.33
SLC22A1 O15245 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538611 0.84 AKR1C1 (0.38) PRCPSIGMAR1OPRM1AKR1C1ALDH1A1
Hydrochloric Acid SCHEMBL6926723 0.83 ALDH1A1 (0.39) PRCPSIGMAR1OPRM1OPRD1OPRK1
SCHEMBL6472118 0.79 AKR1C1 (0.38) TACR1PRCPSIGMAR1OPRM1OPRD1
SCHEMBL518236 0.79 AKR1C1 (0.40) PRCPSIGMAR1OPRM1AKR1C1ALDH1A1
SCHEMBL4685647 0.78 OPRM1 (0.33) TACR1PRCPSIGMAR1OPRM1OPRD1
SCHEMBL11325518 0.74 OPRM1 (0.41) PRCPSIGMAR1OPRM1AKR1C1ALDH1A1
SCHEMBL2432531 0.69 TSHR (0.42) PRCPSIGMAR1OPRM1OPRD1AKR1C1
SCHEMBL2432100 0.68 TSHR (0.44) PRCPSIGMAR1OPRM1OPRD1ALDH1A1
SCHEMBL4636975 0.64 AKR1C1 (0.35) OPRM1OPRD1OPRK1AKR1C1HTT
SCHEMBL11307277 0.64 ALDH1A1 (0.43) OPRM1OPRD1OPRK1ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 TACR1 115/4885PRCP 3729/4885SIGMAR1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.